Allergic Rhinitis Clinical Trial
Official title:
Impact of Pollution on Allergic Rhinitis and Sleep Quality: the POLLAR Study
It has been demonstrated that allergic rhinitis (AR) reduces sleep quality by some components
such as nasal obstruction. Pollution and allergen exposure worsening AR, sleep quality is
deteriorated.
Sleep is associated to physical and mental health, alterations in sleep could explain the
link between AR and work productivity diminution, impairment in daily activities or emotional
problems.
However, interactions between air pollution, sleep and allergic diseases are insufficiently
understood.
The main objective of this study is to determine the impact of pollution and pollens on sleep
parameters.
Over 150 million people have allergic rhinitis (AR) in Europe and around 30% have
uncontrolled AR during allergen exposure. It has been demonstrated that AR reduces sleep
quality by some components such as nasal obstruction. Pollution and allergen exposure
worsening AR, sleep quality is deteriorated.
Sleep is associated to physical and mental health, alterations in sleep could explain the
link between AR and work productivity diminution, impairment in daily activities or emotional
problems.
However, interactions between air pollution, sleep and allergic diseases are insufficiently
understood.
Moreover, the prevalence of OSA in patients with AR is higher than in subjects without AR.
Nasal obstruction could explain the increased risk of OSA.
This prospective, open study will compare sleep quality in 2 different groups: AR patients
and patients without AR during the pollen season and outside the pollen season.The main
objective is to determine the impact of pollution and pollens on sleep parameters for
subjects with AR
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05080322 -
Efficacy and Safety of On-demand and Continuous Administration of Nasal Spray in the Treatment of Allergic Rhinitis
|
Phase 4 | |
| Recruiting |
NCT06028490 -
A Study of IL4Rα Monoclonal Antibody in Patients With Uncontrolled Seasonal Allergic Rhinitis.
|
Phase 2 | |
| Completed |
NCT04388358 -
Traditional Chinese Medicine for the Treatment of Perennial Allergic Rhinitis on Gut Microbiota and Immune-modulation
|
N/A | |
| Recruiting |
NCT04202263 -
Assessment of Suppression of Cutaneous Allergic Responses and Pruritis by Topical Minocycline
|
Phase 2 | |
| Completed |
NCT04078009 -
Standardising Nasal Allergen Challenge in Adult With Hay Fever
|
N/A | |
| Completed |
NCT03644680 -
Changes in Adaptive Immune Responses and Effector Cell Responses Upon Nasal Allergen Exposure - a Pilot Study
|
N/A | |
| Completed |
NCT04541004 -
Adolescent Mite Allergy Safety Evaluation
|
Phase 3 | |
| Recruiting |
NCT05378594 -
HDM and Silver Birch NAC Standardisation
|
N/A | |
| Not yet recruiting |
NCT05684380 -
Efficacy and Safety of MAZ-101 in the Treatment of Persistent Allergic Rhinitis (PER)
|
Phase 3 | |
| Completed |
NCT02943720 -
ATIBAR - Efficacy and Safety of Two Doses of AllerT in Patients Allergic to Birch Pollen
|
Phase 2 | |
| Completed |
NCT02910401 -
Clinical Response to Rhinovirus Challenge
|
Phase 2 | |
| Not yet recruiting |
NCT01014325 -
Safety and Efficacy Study With Allergen Extracts of House Dust Mites for Specific Sublingual Immunotherapy
|
Phase 3 | |
| Completed |
NCT02556801 -
Efficacy and Safety of SUBLIVAC Phleum for Immunotherapy of Grass Pollen-Allergy
|
Phase 2 | |
| Completed |
NCT02352168 -
Airway Inflammation in Children With Allergic Rhinitis and Intervention
|
N/A | |
| Not yet recruiting |
NCT02233426 -
Effect of Hypertonic Solutions on Allergic Rhinitis Patients
|
N/A | |
| Completed |
NCT01946035 -
Alpha-Blockers in Allergic Rhinitis (MAN 01)
|
Phase 4 | |
| Completed |
NCT01918956 -
PURETHAL Birch RUSH Study
|
Phase 4 | |
| Completed |
NCT01682070 -
SUBLIVAC FIX Phleum Pratense DT/DRF
|
Phase 2 | |
| Recruiting |
NCT01454492 -
The Relationship Between Allergic Rhinitis and Geographic Tongue
|
N/A | |
| Completed |
NCT01438463 -
PURETHAL® Mites Dose Range Finding Study in Patients With Persistent Allergic Rhinitis/Rhinoconjunctivitis
|
Phase 2 |